Canada’s Drug Agency (CDA-AMC) received a request to investigate the experiences of health care institutions with their low-field MRI units, including portable or point-of-care units, to support facilities that are considering this technology.
Canada’s Drug Agency (CDA-AMC) received a request to investigate the experiences of health care institutions with their low-field MRI units, including portable or point-of-care units, to support facilities that are considering this technology.